Key result
Targeting RAGE-DIAPH1 cuts myocardial and skeletal muscle lipid accumulation in diabetic mice.
Why the study?
RAGE and DIAPH1 mediate diabetic complications, but whether cardiac and skeletal muscle metabolite changes in type 1 diabetes are influenced by Ager or Diaph1 deletion or RAGE-DIAPH1 blockade was unclear.
Does pharmacological blockade or genetic deletion of the RAGE-DIAPH1 pathway reduce cardiac and skeletal muscle triglycerides in a murine model of type 1 diabetes?
Does pharmacological blockade or genetic deletion of the RAGE-DIAPH1 pathway reduce cardiac and skeletal muscle triglycerides in a murine model of type 1 diabetes?
This preclinical study demonstrates that non-invasive 1H-MRS and MRI can successfully detect triglyceride reductions associated with RAGE/DIAPH1 pathway inhibition in diabetic mice.
These murine data should not change practice; hypothesis-generating for RAGE-DIAPH1 inhibition in human diabetic cardiomyopathy.
Diabetes affects metabolism and metabolite concentrations in multiple organs. Previous preclinical studies have shown that receptor for advanced glycation end products (RAGE, gene symbol Ager ) and its cytoplasmic domain binding partner, Diaphanous‐1 (DIAPH1), are key mediators of diabetic micro‐ and macro‐vascular complications. In this study, we used 1 H‐Magnetic Resonance Spectroscopy (MRS) and chemical shift encoded (CSE) Magnetic Resonance Imaging (MRI) to investigate the metabolite and water‐fat fraction in the heart and hind limb muscle in a murine model of type 1 diabetes (T1D) and to determine if the metabolite changes in the heart and hind limb are influenced by (a) deletion of Ager or Diaph1 and (b) pharmacological blockade of RAGE‐DIAPH1 interaction in mice. Nine cohorts of male mice, with six mice per cohort, were used: wild type non‐diabetic control mice (WT‐NDM), WT‐diabetic (WT‐DM) mice , Ager knockout non‐diabetic (RKO‐NDM) and diabetic mice (RKO‐DM ), Diaph1 knockout non‐diabetic (DKO‐NDM), and diabetic mice (DKO‐DM), WT‐NDM mice treated with vehicle, WT‐DM mice treated with vehicle, and WT‐DM mice treated with RAGE229 (antagonist of RAGE‐DIAPH1 interaction). A Point Resolved Spectroscopy (PRESS) sequence for 1 H‐MRS, and multi‐echo gradient recalled echo (GRE) for CSE were employed. Triglycerides, and free fatty acids in the heart and hind limb obtained from MRS and MRI were compared to those measured using biochemical assays. Two‐sided t‐test, non‐parametric Kruskal‐Wallis Test, and one‐way ANOVA were employed for statistical analysis. We report that the results were well‐correlated with significant differences using MRI and biochemical assays between WT‐NDM and WT‐DM, as well as within the non‐diabetic groups, and within the diabetic groups. Deletion of Ager or Diaph1 , or treatment with RAGE229 attenuated diabetes‐associated increases in triglycerides in the heart and hind limb in mice. These results suggest that the employment of 1 H‐MRS/MRI is a feasible non‐invasive modality to monitor metabolic dysfunction in T1D and the metabolic consequences of interventions that block RAGE and DIAPH1.
No takes yet. Share an insight, caveat, or question.
Menon et al. (2024) studied Type 1 Diabetes (n=54). RAGE229 or Ager/Diaph1 deletion vs. Vehicle or wild-type diabetic control was evaluated on Myocardial triglycerides and fat fraction measured by 1H-MRS and CSE-MRI (p=<0.005). Genetic deletion of Ager or Diaph1, or pharmacological treatment with RAGE229, significantly reduced diabetes-associated increases in triglycerides and fat fraction in the heart and hind limb of mice (p<0.005).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: